Feature Article

Lipid management – what counts, what is new?

Feature Article

Lipid management – what counts, what is new?

LEON A. SIMONS

Figures

© lightspring/shutterstock
© lightspring/shutterstock

Abstract

People with elevated lipid levels are at increased risk of developing cardiovascular disease. Lipid-lowering therapies including statins, ezetimibe and PCSK9 inhibitors have been shown to mitigate these risks. A number of new therapies are in the pipeline that show efficacy in lipid management.

Key Points

  • Lipid-modifying therapy will reduce cardiovascular disease (CVD) risk in many patients, especially in those with pre-existing CVD.
  • There remains a large unmet need for better CVD prevention via lipid control.
  • Many patients are not receiving lipid therapy according to guidelines.
  • In addition to statins and ezetimibe, PCSK9 inhibitors offer additional CVD prevention.
  • There are several new drugs in development that will assist in lipid management.
  • The guidance underlying lipid management is clear – intensive lipid therapy is required in secondary prevention and less intensive therapy, applied selectively, is required in primary prevention.